SEARCH

SEARCH BY CITATION

References

  • Avdulov N. A., Chochina S. V., Igbavboa U., Vassiliev A. V. and Wood W. G. (1997) Lipid binding to amyloid β-peptide: Preferential binding of cholesterol as compared with phosphatidylcholine and fatty acids. J. Neurochem. 69, 17461752.
  • Barrett P. J., Song Y., Van Horn W. D., Hustedt E. J., Schafer J. M., Hadziselimovic A., Beel A. J. and Sanders C. R. (2012) The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science 336, 11681171.
  • Borroni V. and Barrantes F. J. (2011) Cholesterol modulates the rate and mechanism of acetylcholine receptor internalization. J. Biol. Chem. 286, 1712217132.
  • Brown M. S. and Goldstein J. L. (1986) A receptor-mediated pathway for cholesterol homeostasis. Science 232, 3447.
  • Burns M. P. and Rebeck G. W. (2010) Intracellular cholesterol homeostasis and amyloid precursor protein processing. Biochim. Biophys. Acta 1801, 853859.
  • Burns M. P., Igbavboa U., Wood W. G. and Duff K. (2006) Cholesterol distribution, not total levels, correlate with altered amyloid precursor protein processing in statin-treated mice. NeuroMol. Med. 8, 319328.
  • Castellano J. M., Kim J., Stewart F. R. et al. (2011) Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci. Transl. Med. 3, 89ra57.
  • Cedazo-Mínguez A., Hamker U., Meske V., Veh R. W., Hellweg R., Jacobi C., Albert F., Cowburn R. F. and Ohm T. G. (2001) Regulation of apolipoprotein E secretion in rat primary hippocampal astrocyte cultures. Neuroscience 105, 651661.
  • Christensen D. J., Ohkubo N., Oddo J., Van Kanegan M. J., Neil J. E., Li F. Q., Colton C. A. and Vitek M. P. (2011) Apolipoprotein E and peptide mimetics mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. J. Immunol. 186, 25352542.
  • Cole S. L. and Vassar R. (2006) Isoprenoids and Alzheimer's disease: a complex relationship. Neurobiol. Dis. 22, 209222.
  • Corbin J., Wang H. H. and Blanton M. P. (1998) Identifying the cholesterol binding domain in the nicotinic acetylcholine receptor with [125I]azido-cholesterol. Biochim. Biophys. Acta 1414, 6574.
  • Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Jr, Small G. W., Roses A. D., Haines J. L. and Pericak-Vance M. A. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921923.
  • Corder E. H., Saunders A. M., Risch N. J. et al. (1994) Protective effects of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 7, 180184.
  • Daviglus M. L., Bell C. C., Berrettini W. et al. (2010) National Institues of Health state-of-the-science conference statement: preventing Alzheimer's disease and cognitive decline. NIH Consens. State Sci. Statements 27, 130.
  • Dekroon R. M. and Armati P. J. (2001) Synthesis and processing of apolipoprotein E in human brain cultures. Glia 33, 298305.
  • Désiré L., Bourdin J., Loiseau N. et al. (2005) Rac1 inhibition targets amyloid precursor protein processing by gamma-secretase and decreases abeta production in vitro and in vivo. J. Biol. Chem. 280, 3751637525.
  • Di Scala C., Yahi N., Lelièvre C., Garmy N., Chahinian H. and Fantini J. (2013) Biochemical identification of a linear cholesterol-binding domain within Alzheimer's β amyloid peptide. ACS Chem. Neurosci. 20, 509517.
  • Dietschy J. M. and Turley S. D. (2004) Cholesterol metabolism in the central nervous system during early development and in the mature animal. J. Lipid Res. 45, 13751397.
  • Downward J. (2003) Targeting RAS signalling pathways in cancer therapy. Nat. Cancer Rev. 3, 1122.
  • Eckert G. P., Cairns N. J., Maras A., Gattaz W. F. and Müller W. E. (2000) Cholesterol modulates the membrane disordering effects of β-amyloid peptides in the hippocampus: Specific changes in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 11, 181186.
  • Eckert G. P., Hooff G. P., Strandjord D. M., Igbavboa U., Volmer D. A., Müller W. E. and Wood W. G. (2009) Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered in male Alzheimer patients. Neurobiol. Dis. 35, 251257.
  • Eckert G. P., Wood W. G. and Müller W. E. (2010) Lipid membranes and beta-amyloid: a harmful connection. Curr. Protein Pept. Sci. 11, 319325.
  • Eckert G. P., Reik C. and Muller W. E. (2013) Simvastatin alters membrane cholesterol distribution and beta-amyloid levels in brains of APP751SL mice. Pharmazie 68, 590594.
  • Erickson M. A. and Banks W. A. (2013) Blood-brain barrier dysfunction as cause and consequence of Alzheimer's disease. J. Cereb. Blood Flow Metab. 33, 114.
  • Farrer L. A., Cupples L. A., Haines J. L., Hyman B. T., Kukull W. A., Mayeux R., Myers R. H., Pericak-Vance M. A., Risch N. and van Duijn C. M. (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium. JAMA 278, 13491356.
  • Gamba P., Testa G., Sottero B., Gargiulo S., Poli G. and Leonarduzzi G. (2012) The link between altered cholesterol metabolism and Alzheimer's disease. Ann. N. Y. Acad. Sci. 1259, 5464.
  • Gärtner U., Holzer M., Heumann R. and Arendt T. (1995) Induction of p21ras in Alzheimer pathology. NeuroReport 10, 14411444.
  • Gärtner U., Holzer M. and Arendt T. (1999) Elevated expression of p21ras is an early event in Alzheimer's disease and precedes neurofibrillary degeneration. Neuroscience 91, 15.
  • Go A. S., Mozaffarian D., Roger V. L. et al. and on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2013) Heart disease and stroke statistics-2013 Update: a report from the American Heart Association. Circulation 127, e6e245.
  • Gong J. S., Kobayashi M., Hayashi H., Zou K., Sawamura N., Fujita S. C., Yanagisawa K. and Michikawa M. (2002) Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human apoE3 and apoE4 knock-in mice. J. Biol. Chem. 277, 2991929926.
  • Halford R. W. and Russel D. W. (2009) Reduction of cholesterol synthesis in the mouse brain does not affect amyloid formation in Alzheimer's disease, but does extend lifespan. Proc. Natl Acad. Sci. USA 106, 35023506.
  • Hanson M. A., Cherezov V., Griffith M. T., Roth C. B., Jaakola V.-P., Chien E. Y. T., Velasquez J., Kuhn P. and Stevens R. C. (2008) A specific cholesterol binding site is established by the 2.8 A structure of the human β2-adrenergic receptor. Structure 16, 897905.
  • Hayashi H., Igbavboa U., Hamanaka H., Kobayashi M., Fujita S. C., Wood W. G. and Yanagisawa K. (2002) Cholesterol is increased in the exofacial leaflet of synaptic plasma membranes of human apolipoprotein E4 knock-in mice. NeuroReport 13, 383386.
  • Head B. P., Patel H. H. and Insel P. A. (2014) Interaction of membrane/lipid rafts with the cytoskelton: impact on signaling and function: membrane/lipid rafts, mediators of cytoskeletal arrangement and cell signaling. Biochim. Biophys. Acta, 1838, 532545.
  • Hebert L. E., Weuve J., Scherr P. A. and Evans D. A. (2013) Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 80, 17781783.
  • Heino S., Lusa S., Somerharju P., Ehnholm C., Olkkonen V. M. and Ikonen E. (2000) Dissecting the role of the Golgi complex and lipid rafts in biosynthetic transport of cholesterol to the cell surface. Proc. Natl Acad. Sci. USA 97, 83758380.
  • Herman G. E. and Kratz L. (2012) Disorders of sterol synthesis: beyond Smith-Lemli-Opitz syndrome. Am. J. Med. Genet. C Semin. Med. Genet. 160, 301321.
  • Heverin M., Bogdanovic N., Lutjohann D., Bayer T. A., Pikuleva I., Bretillon L., Diczfalusy U., Winblad B. and Björkhem I. (2004) Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. J. Lipid Res. 45, 186193.
  • Hirsch-Reinshagen V. and Wellington C. L. (2007) Cholesterol metabolism, apolipoprotein E, adenosine triphosphate-binding cassette transporters, and Alzheimer's disease. Curr. Opin. Lipidol. 18, 325332.
  • Holtzman D. M., Bales K. R., Tenkova T., Sartorius L., Paul S. M., Bales K., Ashe K. H., Irizarry M. C. and Hyman B. T. (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 97, 28922897.
  • Holtzman D. M., Herz J. and Bu G. (2012) Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb. Perspect. Med. 3, a006312.
  • Hooff G. P., Wood W. G., Müller W. E. and Eckert G. P. (2010) Isopernoids, small GTPases and Alzheimer's disease. Biochim. Biophys. Acta 1801, 896905.
  • Hooff G. P., Wood W. G., Hyun K. J., Igbavboa U., Ong W. Y., Müller W. E. and Eckert G. P. (2012) Brain isoprenoids farnesyl pyrophosphate and geranylgeranyl pyrophosphate are increased in aged mice. Mol. Neurobiol. 46, 179185.
  • Horton J. D., Goldstein J. L. and Brown M. S. (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 11251131.
  • Hu J., LaDu M. J. and Van Eldik L. J. (1998) Apolipoprotein E attenuates beta-amyloid-induced astrocyte activation. J. Neurochem. 71, 16261634.
  • Huesa G., Baltrons M. A., Gómez-Ramos P., Morán A., García A., Hidalgo J., Francés S., Santpere G. and Galea E. (2010) Altered distribution of RhoA in Alzheimer's disease and abetaPP overexpressing mice. J. Alzheimers Dis. 19, 3756.
  • Igbavboa U., Avdulov N. A., Schroeder F. and Wood W. G. (1996) Increasing age alters transbilayer fluidity and cholesterol asymmetry in synaptic plasma membranes of mice. J. Neurochem. 66, 17171725.
  • Igbavboa U., Avdulov N. A., Chochina S. V. and Wood W. G. (1997) Transbilayer distribution of cholesterol is modified in brain synaptic plasma membranes of knockout mice deficient in the low density lipoprotein receptor, apolipoprotein E, or both proteins. J. Neurochem. 69, 16611667.
  • Igbavboa U., Pidcock J. M., Johnson L. N. A., Malo T. M., Studniski A., Sun G. Y. and Wood W. G. (2003) Cholesterol distribution in the Golgi complex of DITNC1 astrocytes is differentially altered by fresh and aged amyloid beta-peptide1-42. J. Biol. Chem. 278, 1715017157.
  • Igbavboa U., Eckert G. P., Malo T. M. et al. (2005) Murine synaptosomal lipid raft protein and lipid composition are altered by expression of human apoE3 and 4 and by increasing age. J. Neurol. Sci. 229–230, 225232.
  • Igbavboa U., Johnson-Anuna L. N., Rossello X., Butterick T. A., Sun G. Y. and Wood W. G. (2006) Amyloid beta-protein 1-42 increases cAMP and apolipoprotein E levels which are inhibited by β1 and β2-adrenergic receptor antagonists in mouse primary astrocytes. Neuroscience 142, 655660.
  • Igbavboa U., Sun G. Y., Weisman G. A. and Wood W. G. (2009) Amyloid β-protein stimulates trafficking of cholesterol and caveolin-1 from the plasma membrane to the Golgi complex in mouse primary astrocytes. Neuroscience 162, 328338.
  • Jarvik G. P., Wijsman E. M., Kukull W. A., Schellenberg G. D., Yu C. and Larson E. B. (1995) Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 45, 10921096.
  • Junker V., Becker A., Hühne R., Zembatov M., Ravati A., Culmsee C. and Krieglstein J. (2002) Stimulation of β-adrenoceptors activates astrocytes and provides neuroprotection. Eur. J. Pharmacol. 446, 2536.
  • Kabara J. J. (1973) A critical review of brain cholesterol metabolism. Prog. Brain Res. 40, 363382.
  • Karasinska J. M. and Hayden M. R. (2011) Cholesterol metabolism in Huntington disease. Nat. Rev. Neurol. 7, 561572.
  • Kim J., Basak J. M. and Holtzman D. M. (2009) The role of apolipoprotein E in Alzheimer's disease. Neuron 63, 287303.
  • Kirsch C., Eckert G. P., Koudinov A. R. and Müller W. E. (2003a) Brain cholesterol, statins and Alzheimer's Disease. Pharmacopsychiatry 36, S113S119.
  • Kirsch C., Eckert G. P. and Müller W. E. (2003b) Statin effects on cholesterol micro-domains in brain plasma membranes. Biochem. Pharmacol. 65, 843856.
  • Kivipelto M., Helkala E.-L., Laakso M. P., Hänninen T., Hallikainen M., Alhainen K., Soininen H., Tuomilehto J. and Nissien A. (2001) Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal population based study. BMJ 322, 14471451.
  • Knittweis J. W. and McMullen W. A. (2000) The effect of apoE on dementia is not through atherosclerosis: the rotterdam study: to the editor. Neurology 54, 23562358.
  • Korade Z. and Kenworthy A. K. (2008) Lipid rafts, cholesterol, and the brain. Neuropharmacology 55, 12651273.
  • Kotti T. J., Ramirez D. M., Pfeiffer B. E., Huber K. M. and Russell D. W. (2006) Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc. Natl Acad. Sci. USA 103, 38693874.
  • Kotti T. J., Head D. D., McKenna C. E. and Russell D. W. (2008) Biphasic requirement for geranylgeraniol in hippocampal long-term potentiation. Proc. Natl Acad. Sci. USA 105, 1139411399.
  • Koudinov A. R., Koudinova N. V. and Berezov T. T. (1996) Alzheimer's peptides Aβ1-40 and Aβ1-28 inhibit the plasma cholesterol esterification rate. Biochem. Mol. Biol. Int. 38, 747752.
  • Koudinova N. V., Berezov T. T. and Koudinov A. R. (1996) Multiple inhibitory effects of Alzheimer's peptide Aβ1-40 on lipid biosynthesis in cultured human HepG2 cells. FEBS Lett. 395, 204206.
  • van de Kraats C., Killestein J., Popescu V., Rijkers E., Vrenken H., Lütjohann D., Barkhof F., Polman C. and Teunissen C. (2014) Oxysterols and cholesterol precursors correlate to magnetic resonance imaging measures of neurodegeneration in multiple sclerosis. Mult. Scler, 20, 412417.
  • Kuo Y.-M., Emmerling M. R., Bisgaier C. L., Essenburg A. D., Lampert H. C., Drumm D. and Roher A. E. (1998) Elevated low-density lipoprotein in Alzheimer's disease correlates with brain Aβ 1-42 levels. Biochem. Biophys. Res. Commun. 252, 711715.
  • LaDu M. J., Shah J. A., Reardon C. A., Getz G. S., Bu G., Hu J., Guo L. and Van Eldik L. J. (2000) Apolipoprotein E receptors mediate the effects of β-amyloid on astrocyte cultures. J. Biol. Chem. 275, 3397433980.
  • LaDu M. J., Shah J. A., Reardon C. A., Getz G. S., Bu G., Hu J., Guo L. and Van Eldik L. J. (2001) Apolipoprotein E and apolipoprotein E receptors modulate Aβ-induced glial neuroinflammatory responses. Neurochem. Int. 39, 427434.
  • de Lau M. L., Koudstaal P. J., Hofman A. and Breteler M. M. B. (2006) Serum cholesterol levels and the risk of Parkinson's disease. Am. J. Epidemiol. 164, 9981002.
  • Laureys G., Clinckers R., Gerlo S., Spooren A., Wilczak N., Kooijman R., Smolders I., Michhhhotte Y. and De Keyser J. (2010) Astrocytic beta(2)-adrenergic receptors: from physiology to pathology. Prog. Neurobiol. 91, 189199.
  • Lazar A. N., Bich C., Panchal M. et al. (2013) Time-of-flight secondary ion mass spectrometry (TOF-SIMS) imaging reveals cholesterol overload in the cerebral cortex of Alzheimer disease patients. Acta Neuropathol. 125, 133144.
  • Lee A. G. (2011) Biological membranes: the importance of molecular detail. Trends Biochem. Sci. 36, 493500.
  • Leoni V., Long J. D., Mills J. A., Di Donato S., Paulsen J. S. and the members of the PREDICT-HD study group (2013) Plasma 24S-hydroxycholesterol correlation with markers of Huntington disease progression. Neurobiol. Dis. 55, 3743.
  • Li G., Shofer J. B., Kukull W. A. et al. (2005) Serum cholesterol and risk of Alzheimer disease: a community-based cohort study. Neurology 65, 10451050.
  • Li F. Q., Fowler K. A., Neil J. E., Colton C. A. and Vitek M. P. (2010) An apolipoprotein E-mimetic stimulates axonal regeneration and remyelination after peripheral nerve injury. J. Pharmacol. Exp. Ther. 334, 106115.
  • Li L., Zhang W., Cheng S. and Cao D. (2012) Isoprenoids and related pharmacological interventions: Potential application in Alzheimer's disease. Mol. Neurobiol. 46, 6477.
  • Liao J. K. and Laufs U. (2004) Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 45, 89118.
  • Liguori N., Nerenberg P. S. and Head-Gordon T. (2013) Embedding Aβ42 in heterogeneous membranes depends on cholesterol asymmetries. Biophys. J. 105, 899910.
  • Linseman D. A. and Loucks F. A. (2008) Diverse roles of Rho family GTPases in neuronal development, survival, and death. Front. Biosci. 13, 657676.
  • Liu Y., Peterson D. A. and Schubert D. (1998) Amyloid β peptide alters intracellular vesicle trafficking and cholesterol homeostasis. Proc. Natl Acad. Sci. USA 95, 1326613271.
  • Liu C. C., Kanekiyo T., Xu H. and Bu G. (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 9, 106118.
  • Lund E. G., Xie C., Kotti T., Turley S. D., Dietschy J. M. and Russell D. W. (2003) Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J. Biol. Chem. 278, 2298022988.
  • Lütjohann D. and von Bergmann K. (2003) 24S-hydroxycholesterol: a marker of brain cholesterol metabolism. Pharmacopsychiatry 36, S102S106.
  • Ma Q.-L., Yang F., Calon F., Ubeda O. J., Hansen J. E., Weisbart R. H., Beech W., Frautschy S. A. and Cole G. M. (2008) p21-activated Kinase-aberrant Activation and Translocation in Alzheimer Disease Pathogenesis. J. Biol. Chem. 283, 1413214143.
  • Mahley R. W. (1988) Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 240, 622630.
  • Mans R. A., McMahon L. L. and Li L. (2012) Simvastatin-mediated enhancement of lonf-term potentiation is driven by farnesyl-pyrophosphate depletion and inhibition of farnesylation. Neuroscience 202, 19.
  • Martin V., Fabelo N., Santpere G., Puig B., Marin R., Ferrer I. and Díaz M. (2010) Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex. J. Alzheimers Dis. 19, 489502.
  • Mason R. P., Shoemaker W. J., Shajenko L., Chambers T. E. and Herbette L. G. (1992) Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol. Neurobiol. Aging 13, 413419.
  • Mason R. P., Estermyer J. D., Kelly J. F. and Mason P. E. (1996) Alzheimer's disease amyloid beta peptide 25-35 is localized in the membrane hydrocarbon core: X-ray diffraction analysis. Biochem. Biophys. Res. Commun. 222, 7882.
  • Matsuo M., Togawa M., Hirabaru K., Mochinaga S., Narita A., Adachi M., Egashira M., Irie T. and Ohno K. (2013) Effects of cyclodextrin in two patients with Niemann-Pick Type C disease. Mol. Genet. Metab. 108, 7681.
  • Maulik M., Westaway D., Jhamandas J. H. and Kar S. (2013) Role of cholesterol in APP metabolism and its significance in Alzheimer's disease pathogenesis. Mol. Neurobiol. 47, 3763.
  • McGuinness B., O'Hare J., Craig D., Bullock R., Malouf R. and Passmore P. (2013) Cochrane review on ‘Statins for the treatment of dementia’. Int. J. Geriatr. Psychiatry 28, 119126.
  • McTaggart S. J. (2006) Isoprenylated proteins. Cell. Mol. Life Sci. 63, 255267.
  • Mendez A. J. (1995) Monensin and brefeldin A inhibit high density lipoprotein-mediated cholesterol efflux from cholesterol-enriched cells: Implications for intracellular cholesterol transport. J. Biol. Chem. 270, 58915900.
  • Mendoza-Naranjo A., Gonzalez-Billault C. and Maccioni R. B. (2007) 1-42 stimulates actin polymerization in hippocampal neurons through Rac1 and CDC42 Rho GTPases. J. Cell Sci. 120, 279288.
  • Michikawa M., Fan Q.-W., Isobe I. and Yanagisawa K. (2000) Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J. Neurochem. 74, 10081016.
  • Michikawa M., Gong J.-S., Fan Q.-W., Sawamura N. and Yanagisawa K. (2001) A novel action of Alzheimer's amyloid β-protein (Aβ): Oligomeric Aβ promotes lipid release. J. Neurosci. 18, 72267235.
  • Mo H., Yeganehjoo H., Shah A., Mo W. K., Soelaiman I. N. and Shen C.-L. (2012) Mevalonate-suppressive dietary isoprenoids for bone health. J. Nutr. Biochem. 23, 15431551.
  • Mohamed A., Saavedra L., Di Pardo A., Sipione S. and Posse de Chaves E. (2012) β-amyloid inhibits protein prenylation and induces cholesterol sequestration by impairing SREBP-2 cleavage. J. Neurosci. 32, 64906500.
  • Nicholson A. M. and Ferreira A. (2009) Increased membrane cholesterol might render mature hippocampal neurons more susceptible to beta-amyloid-induced calplain activation and tau toxicity. J. Neurosci. 29, 46404651.
  • Nixon R. A. (2004) Niemann-Pick Type C disease and Alzheimer's disease: the APP-endosome connection fattens up. Am. J. Pathol. 164, 757761.
  • North P. and Fleischer S. (1983) Alteration of synaptic membrane cholesterol/phospholipid ratio using a lipid transfer protein. J. Biol. Chem. 258(2), 12421253.
  • Oh D., Han S., Seo J. et al. (2010) Regulation of synaptic Rac1 activity, long-term potentiation maintenance, and learning and memory by BCR and ABR Rac GTPase-activating proteins. J. Neurosci. 30, 1413414144.
  • Ong W. Y., Tanaka K., Dawe G. S., Ittner L. M. and Farooqui A. A. (2013) Slow excitotoxicity in Alzheimer's disease. J. Alzheimers Dis. 35, 643668.
  • Papassotiropoulos A., Lutjohann D., Bagli M., Locatelli S., Jessen F., Buschfort R., Ptok U., Bjorkhem I., von Bergmann K. and Heun R. (2002) 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J. Psychiatr. Res. 36, 2732.
  • Pappolla M. A., Bryant-Thomas T., Herbert D. et al. (2003) Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 61, 199205.
  • Parton R. G. and del Pozo M. A. (2013) Caveolae as plasma membranes sensors, protectors and organizers. Nat. Rev. Mol. Cell Biol. 14, 98112.
  • Passarelli M. K. and Winograd N. (2013) Lipid imaging with time-of-flight secondary ion mass spectrometry (ToF-SIMS). Biochim. Biophys. Acta 1811, 976990.
  • Pierrot N., Tyteca D., D'auria L. et al. (2013) Amyloid precursor protein controls cholesterol turnover needed for neuronal activity. EMBO Mol. Med. 5, 608625.
  • Pilpel Y. and Segal M. (2004) Activation of PKC induces rapid morphol-ogical plasticity in dendrites of hippocampal neurons via Rac and Rho-dependent mechanisms. Eur. J. Neurosci. 19, 31513164.
  • Poirier J. (1994) Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci. 17, 525530.
  • Poirier J., Davignon J., Bouthillier D., Kogan S., Bertrand P. and Gauthier S. (1993) Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 342, 697699.
  • Popp J., Lewczuk P., Kolsch H., Meichsner S., Kornhuber J., Jessen F. and Lütjohann D. (2012) Cholesterol metabolism is associated with soluble amyloid precursor protein production in Alzheimer's disease. J. Neurochem. 123, 310316.
  • Popp J., Meichsner S., Kölsch H., Lewczuk P., Maier W., Kornhuber J., Jessen F. and Lütjohann D. (2013) Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer's disease. Biochem. Pharmacol. 86, 3742.
  • Posse de Chaves E. I. (2012) Reciprocal regulation of cholesterol and beta amyloid at the subcellular level in Alzheimer's disease. Can. J. Physiol. Pharmacol. 90, 753764.
  • Ramakers G. J. (2002) Rho proteins, mental retardation and the cellular basis of cognition. Trends Neurosci. 25, 191199.
  • Ramirez D. M. O., Andersson S. and Russel D. W. (2008) Neuronal expression and subcellular localization of cholesterol 24-hydroxylase in the mouse brain. J. Comp. Neurol. 507, 16761693.
  • Rapp A., Gmeiner B. and Huttinger M. (2006) Implication of apoE isoforms in cholesterol metabolism by primary rat hippocampal neurons and astrocytes. Biochimie 88, 473483.
  • Rebeck G. W., Kindy M. and LaDu M. J. (2002) Apolipoprotein E and Alzheimer's disease: the protective effects of ApoE2 and E3. J. Alzheimers Dis. 4, 145154.
  • Reddy S. and Comai L. (2012) Lamin A, farnesylation and aging. Exp. Cell Res. 318, 17.
  • Romas S. N., Tang M. X., Berglund L. and Mayeux R. (1999) ApoE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology 53, 517521.
  • Roskoski R. (2003) Protein prenylation: a pivotal posttranslational process. Biochem. Biophys. Res. Commun. 303, 17.
  • Rossello X. S., Igbavboa U., Weisman G. A., Sun G. Y. and Wood W. G. (2012) AP-2β regulates amyloid beta-protein stimulation of apolipprotein E transcription in astrocytes. Brain Res. 1444, 8795.
  • Schroeder F., Gallegos A. M., Atshaves B. P. et al. (2001) Recent advances in membrane microdomains: Rafts, caveolae, and intracellular cholesterol trafficking. Exp. Biol. Med. 226, 873890.
  • Schroeder F., Huang H., McIntosh A. L., Atshaves B. P. and Kier A. B. (2010) Caveolin, sterol carrier protein-2, membrane cholesterol-rich microdomains and intracellular cholesterol trafficking. Subcell. Biochem. 51, 279318.
  • Sekino Y., Kojima N. and Shirao T. (2007) Role of actin cytoskelton in dendritic spine morphogenesis. Neurochem. Int. 51, 92104.
  • Solomon A., Kivipelto M., Wolozin B., Zhou J. and Whitmer R. A. (2009a) Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement. Geriatr. Cogn. Disord. 28, 7580.
  • Solomon A., Leoni V., Kivipelto M. et al. (2009b) Plasma levels of 24S-hydroxycholesterol reflect brain volumes in patients without objective cognitive impairment but not in those with Alzheimer's disease. Neurosci. Lett. 462, 8993.
  • Sonnino S. and Prinetti A. (2013) Membrane domains and the “lipid raft” concept. Curr. Med. Chem. 20, 421.
  • Sparks D. L. (1997) Coronary artery disease, hypertension, apoE, and cholesterol: a link to Alzheimer's disease? Ann. N. Y. Acad. Sci. 826, 128146.
  • Sparks D. L., Hunsaker J. C., III, Scheff S. W., Kryscio R. J., Henson J. L. and Markesbery W. R. (1990) Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol. Aging 11, 601607.
  • Sparks D. L., Scheff S. W., Hunsaker J. C., III, Liu H., Landers T. and Gross D. R. (1994) Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 126, 8894.
  • Stewart R., White L. R., Xue Q.-L. and Launer L. J. (2007) Twenty-six-year change in total cholesterol levels and incident dementia. Arch. Neurol. 64, 103107.
  • Strittmatter W. J. and Roses A. D. (1996) Apolipoprotein E and Alzheimer's disease. Annu. Rev. Neurosci. 19, 5377.
  • Tan Z. S., Seshadri S., Beiser A., Wilson P. W. F., Kiel D. P., Tocco M., D'Agostino R. B. and Wolf P. A. (2003) Plasma total cholesterol level as a risk factor for Alzheimer disease. Arch. Intern. Med. 163, 10531057.
  • Tolias K. F., Duman J. G. and Um K. (2011) Control of synapse development and plasticity by Rho GTPase regulatory proteins. Prog. Neurobiol. 94, 133148.
  • Vance J. E., Hayashi H. and Karten B. (2005) Cholesterol homeostasis in neurons and glial cells. Semin. Cell Dev. Biol. 16, 193212.
  • Verghese P. B., Castellano J. M. and Holtzman D. M. (2011) Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol. 10, 241252.
  • Verghese P. B., Castellano J. M., Garai K., Wang Y., Jiang H., Shah A., Bu G., Frieden C. and Holtzman D. M. (2013) ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions. Proc. Natl Acad. Sci. USA 110, 18071816.
  • Wang H., Durham L., Dawson H., Song P., Warner D. S., Sullivan P. M., Vitek M. P. and Laskowitz D. T. (2007) An apolipoprotein E-based therapeutic improves outcome and reduces Alzheimer's disease pathology following closed head injury: evidence of pharmacogenomic interaction. Neuroscience 144, 13241333.
  • Wang P.-L., Niidome T., Akaike A., Kihara T. and Sugimoto H. (2009) Rac1 inhibition negatively regulates transcriptional activity of the amyloid precursor protein gene. J. Neurosci. Res. 87, 21052114.
  • Wang D., Govindaiah G., Liu R., De Arcangelis V., Cox C. L. and Xiang Y. K. (2010) Binding of amyloid beta peptide to beta2 adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity. FASEB J. 24, 35113521.
  • Weber M. S., Prod'homme T., Steinman L. and Zamvil S. S. (2005) Drug Insight: using statins to treat neuroinflammatory disease. Nat. Clin. Pract. Neurol. 1, 106112.
  • Whitmer R. A., Sidney S., Selby J., Johnston C. and Yaffe K. (2005) Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64, 277281.
  • Wiemer A. J., Hohl R. J. and Wiemer D. F. (2009) The intermediate enzymes of isoprenoid metabolism as anticancer targets. Anticancer Agents Med. Chem. 9, 526542.
  • Williamson R. and Sutherland C. (2011) Neuronal membranes are key to the pathogenesis of Alzheimer's disease: the role of both raft and non-raft membrane domains. Curr. Alzheimer Res. 8, 213221.
  • Wolf A., Bauer B. and Hartz A. M. S. (2012) ABC transporters and the Alzheimer's disease enigma. Front. Psychiartry 3, 114.
  • Wood W. G., Gorka C. and Schroeder F. (1989) Acute and chronic effects of ethanol on transbilayer membrane domains. J. Neurochem. 52, 19251930.
  • Wood W. G., Igbavboa U., Rao A. M., Schroeder F. and Avdulov N. A. (1995) Cholesterol oxidation reduces Ca2+ + Mg2 + -ATPase activity, interdigitation, and increases fluidity of brain synaptic plasma membranes. Brain Res. 683, 3642.
  • Wood W. G., Schroeder F., Igbavboa U., Avdulov N. A. and Chochina S. V. (2002) Brain membrane cholesterol domains, aging, and amyloid beta-peptides. Neurobiol. Aging 23, 685694.
  • Wood W. G., Eckert G. P., Igbavboa U. and Müller W. E. (2003) Amyloid beta-peptide interactions with membranes and cholesterol: Causes or casualties of Alzheimer's disease. Biochim. Biophys. Acta 1610, 281290.
  • Wood W. G., Igbavboa U., Eckert G. P., Johnson-Anuna L. N. and Müller W. E. (2005) Is hypercholesterolemia a risk factor for Alzheimer's disease? Mol. Neurobiol. 31, 185192.
  • Wood W. G., Igbavboa U., Eckert G. P. and Müller W. E. (2007) Cholesterol-A janus-faced molecule in the central nervous system, in Handbook of Neurochemistry and Molecular Neurobiology-Neural Membranes and Transport, (Lajtha A. and Reith M. E. A., eds), pp. 151170. Springer, New York.
  • Wood W. G., Igbavboa U., Müller W. E. and Eckert G. P. (2011) Cholesterol asymmetry in synaptic plasma membranes. J. Neurochem. 116, 684689.
  • Yao Z. X. and Papadopoulos V. (2002) Function of beta-amyloid in cholesterol transport: a lead to neurotoxicity. FASEB J. 16, 16771679.
  • Yao J., Ho D., Calingasan N. Y., Pipalia N. H., Lin M. T. and Beal M. F. (2012) Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease. J. Exp. Med. 209, 25012513.
  • Yeagle P. L. (1983) Cholesterol modulation of (Na++K+)-ATPase ATP hydrolyzing activity in the human erythrocyte. Biochim. Biophys. Acta 727, 3944.
  • Ying M., Grimmer S., Iversen T.-G., van Deurs B. and Sandvig K. (2003) Cholesterol loading induces a block in the exit of VSVG from the TGN. Traffic 4, 772784.
  • Zhang J. (2011) Epidemiological link between low cholesterol and suicidality: a puzzle never finished. Nutr. Neurosci. 14, 268287.
  • Zhong N. and Weisgraber K. H. (2009) Understanding the association of apolipoprotein E4 and Alzheimer disease: clues from its structure. J. Biol. Chem. 284, 60276031.